Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Next-generation sequencing (NGS) can identify novel cancer targets. However, interpreting the molecular findings and accessing drugs/clinical trials is challenging. Furthermore, many tumors show resistance to monotherapies. To implement a precision strategy, we initiated a multidisciplinary (basic/t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Shumei, Kim, Ki Hwan, Lim, Hyo Jeong, Boichard, Amelie, Nikanjam, Mina, Weihe, Elizabeth, Kuo, Dennis J., Eskander, Ramez N., Goodman, Aaron, Galanina, Natalie, Fanta, Paul T., Schwab, Richard B., Shatsky, Rebecca, Plaxe, Steven C., Sharabi, Andrew, Stites, Edward, Adashek, Jacob J., Okamura, Ryosuke, Lee, Suzanna, Lippman, Scott M., Sicklick, Jason K., Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532150/
https://www.ncbi.nlm.nih.gov/pubmed/33009371
http://dx.doi.org/10.1038/s41467-020-18613-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532150/
https://www.ncbi.nlm.nih.gov/pubmed/33009371
http://dx.doi.org/10.1038/s41467-020-18613-3

Ejemplares similares